We are in Phase 2 clinical development of three high value cardiometabolic indications.

Our lead program, ninerafaxstat, is currently in Phase 2 clinical development for conditions of oxygen deprivation in the heart. The initial indications we are targeting with ninerafaxstat are non-obstructive hypertrophic cardiomyopathy, heart failure and stable angina.


For the Treatment of Cardiometabolic Disorders

Read more